Join
Live feed
·
PRReleasevia Quantisnow
Celldex Therapeutics Inc. logo

Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026

ByQuantisnow·Wall Street's wire, on your screen.
CLDX· Celldex Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CLDX (Celldex Therapeutics Inc.) and more on Quantisnow.